Issue

Vol. 29 No. 8 (2017): Vol 29 Issue 8

Copyright (c) 2017 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Validation of HPLC-MS Method in Positive Ion Mode for Estimation of Phenytoin in Human Plasma Using Phenytoin D10 as Internal Standard

https://doi.org/10.14233/ajchem.2017.20670
Pallavi Alegete
Department of Chemistry, JNTUH College of Engineering, Nachupally, Jagtial, Karimnagar-505 501, India; Piramal Clinical Research Laboratories, Ramanthapur, Hyderabad-500 013, India
Prasad Kancherla
Institute of Science & Technology, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad-500 085, India
Srinivas Keesari
Piramal Clinical Research Laboratories, Ramanthapur, Hyderabad-500 013, India
Siva Sanker Rao Yedlapalli
Piramal Clinical Research Laboratories, Ramanthapur, Hyderabad-500 013, India
Sathyanarayana Boodida
Department of Chemistry, JNTUH College of Engineering, Nachupally, Jagtial, Karimnagar-505 501, India

Corresponding Author(s) : Sathyanarayana Boodida

bs14@jntuh.ac.in

Asian Journal of Chemistry, Vol. 29 No. 8 (2017): Vol 29 Issue 8

Abstract

A high performance liquid chromatography mass spectrometric method for the estimation of phenytoin, in human plasma in positive ion mode was developed and validated using phenytoin D10 as internal standard (IS). Sample preparation was accomplished by solid-phase extraction technique. The eluted samples were chromatographed on Zorbax Eclipse XDB-Phenyl 4.6 × 75 mm, 3.5 μm (Make: Agilent Technologies) column using a mobile phase consisting of HPLC grade acetonitrile: 0.1 % formic acid (80:20 v/v). The method was validated over a concentration range of 101.253 to 10074. 937 ng mL-1 for phenytoin. This validation report provides the results of selectivity, matrix effect, sensitivity determinations, precision and accuracy data, recovery and dilution integrity along with all pertinent documentation. An open label, balanced, randomized, two-treatment, two-period, two-sequence, cross-over, single oral dose bioequivalence study of phenytoin sodium 100 mg capsules (3 × 100 mg, a total of 300 mg) of Green Evolution Laboratories, India comparing with phenytoin sodium flynn 100 mg hard capsules (3 × 100 mg, a total of 300 mg) of Flynn Pharma Ltd, Alton House, Ireland in healthy, human adult subjects, under fasting conditions was conducted. The 90 % confidence intervals were calculated for the Cmax, AUC(0-t) and AUC(0-¥), giving values between 96.26-110.38 % demonstrating the bioequivalence of the two formulations.

Keywords

Phenytoin Phenytoin-D10 Human plasma LCMS/MS Pharmacokinetic study
Alegete, P., Kancherla, P., Keesari, S., Rao Yedlapalli, S. S., & Boodida, S. (2017). Validation of HPLC-MS Method in Positive Ion Mode for Estimation of Phenytoin in Human Plasma Using Phenytoin D10 as Internal Standard. Asian Journal of Chemistry, 29(8), 1845–1852. https://doi.org/10.14233/ajchem.2017.20670
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. D. Panomvana, N. Khummuenwai, S. Sra-lum and S. Towanabut, Curr. Ther. Res., 68, 325 (2007); https://doi.org/10.1016/j.curtheres.2007.10.007.
  2. D. Blum, M. Reed and A. Metz, Prevalence of Major Affective Disorders and Manic/Hypomanic Symptoms in Persons with Epilepsy: A Community Survey, In: American Academy of Neurology, Denver, CO, USA (2002).
  3. A. Ettinger, M. Reed and J. Cramer, Neurology, 63, 1008 (2004); https://doi.org/10.1212/01.WNL.0000138430.11829.61.
  4. M. Ha-Kaczyñska, Pharmacol. Rep., 59, ••• (2007).
  5. C. Temiz, P. Temiz, A. Demirel, M. Sayin, A.S. Umur and F.D. Özer, J. Clin. Neurosci., 16, 307 (2009); https://doi.org/10.1016/j.jocn.2007.12.007.
  6. C.M. Ohnmacht, S. Chen, Z. Tong and D.S. Hage, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 836, 83 (2006); https://doi.org/10.1016/j.jchromb.2006.03.043.
  7. N.J. Gogtay, S.S. Dalvi, R.B. Mhatre, B.G. Kirodian, A.H. Gupta, S.P. Jadhav and N.A. Kshirsagar, Ther. Drug Monit., 25, 215 (2003); https://doi.org/10.1097/00007691-200304000-00012.
  8. H. Kodama, Y. Kodama, S. Shinozawa, R. Kanemaru, K. Todaka and Y. Mitsuyama, J. Clin. Pharm. Ther., 23, 361 (1998); https://doi.org/10.1046/j.1365-2710.1998.00173.x.
  9. M.C. Meyer, A.B. Straughn, R.M. Mhatre, V.P. Shah, M.-L. Chen, R.L. Williams and L.J. Lesko, Pharm. Res., 18, 394 (2001); https://doi.org/10.1023/A:1011075502215.
  10. M.R. Nuwer, T.R. Browne, W.E. Dodson, F.E. Dreifuss, J. Engel, I.E. Leppik, R.H. Mattson, J. Penry, D.M. Treiman and B.J. Wilder, Neurology, 40, 1647 (1990); https://doi.org/10.1212/WNL.40.11.1647.
  11. P.C. Lin, Y.H. Hsieh, F.F. Liao and S.H. Chen, Electrophoresis, 31, 1572 (2010); https://doi.org/10.1002/elps.200900768.
  12. E.J. Randinitis, R.A. Buchanan and A.W. Kinkel, Epilepsia, 31, 458 (1990); https://doi.org/10.1111/j.1528-1157.1990.tb05503.x.
  13. M. Mikati, N. Bassett and S. Schachter, Epilepsia, 33, 359 (1992); https://doi.org/10.1111/j.1528-1157.1992.tb02328.x.
  14. I. Soryal and A. Richens, J. Neurol. Neurosur. Psych., 55, 688 (1992); https://doi.org/10.1136/jnnp.55.8.688.
  15. G.L. Lensmeyer, B.E. Gidal and D.A. Wiebe, Ther. Drug Monit., 19, 292 (1997); https://doi.org/10.1097/00007691-199706000-00009.
  16. M.M. Bhatti, G.D. Hanson and L. Schultz, J. Pharm. Biomed. Anal., 16, 1233 (1998); https://doi.org/10.1016/S0731-7085(97)00265-3.
  17. K.M. Patil and S.L. Bodhankar, J. Pharm. Biomed. Anal., 39, 181 (2005); https://doi.org/10.1016/j.jpba.2005.02.045.
  18. R.H.C. Queiroz, C. Bertucci, W.R. Malfará, S.A.C. Dreossi, A.R. Chaves, D.A.R. Valério and M.E.C. Queiroz, J. Pharm. Biomed. Anal., 48, 428 (2008); https://doi.org/10.1016/j.jpba.2008.03.020.
  19. T.A.C. Vermeij and P.M. Edelbroek, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 857, 40 (2007); https://doi.org/10.1016/j.jchromb.2007.06.023.
  20. M.J. Cwik, M. Liang, K. Deyo, C. Andrews and J. Fischer, J. Chromatogr. B Biomed. Sci. Appl., 693, 407 (1997); https://doi.org/10.1016/S0378-4347(97)00057-1.
  21. Q. Fenghe, L. Li, L. Yi and L. Yongquan, Se Pu, 13, 218 (1995).
  22. S. Bardin, J.C. Ottinger, A.P. Breau and T.J. O’Shea, J. Pharm. Biomed. Anal., 23, 573 (2000); https://doi.org/10.1016/S0731-7085(00)00338-1.
  23. S.M.N. Roy, S.M. Yetal, V.V. Vaidya and S.S. Joshi, E-J. Chem., 5, 169 (2008); https://doi.org/10.1155/2008/362512.
  24. Y. Zhang, N. Mehrotra, N.R. Budha, M.L. Christensen and B. Meibohm, Clin. Chim. Acta, 398, 105 (2008); https://doi.org/10.1016/j.cca.2008.08.023.
  25. S.L. Dalmora, D.R. Nogueira, L.F. Londero, D.P. Santana and T.M. Goncalves, Lat. Am. J. Pharm., 28, 247 (2009).
  26. M. Achim, D. Muntean, L. Vlase, I. Baldea, D. Mihu and S.E. Leucuta, Stud. Univ. Babes-Bolyai Chem., 54, 7 (2009).
  27. D. Wang, X.Y. Chen and Y.F. Zhang, Zhongguo Lin Chuang Yao Li Xue Za Zhi, 22, 213 (2006).
  28. A. Zarghi, K. Gholami and M. Hessami, Boll. Chim. Farm., 138, 508 (1999).
  29. FDA, Center for Drug Evaluation and Research, US Department of Health and Human Services, Guidance for Industry, Bioanalytical Method Validation (2001).
  30. FDA, Center for Drug Evaluation and Research, US Department of Health and Human Services, Guidance for Industry, Bioavailability and Bioequivalence Studies for Orally Administered Drug Products–General Considerations (2002).
  31. B.K. Matuszewski, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 830, 293 (2006); https://doi.org/10.1016/j.jchromb.2005.11.009.
  32. S.C. Chow and J.P. Liu, Design and Analysis of Bioavailability and Bioequivalence Studies, Marcel Dekker, New York, edn 2 (2000).
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 1 Download : 0